Whalesbook Logo

Whalesbook

  • Home
  • About Us
  • Contact Us
  • News
  • Stocks
  • Premium
Back

Dilip Buildcon's Profit Dips 23%! But Mega Project Wins Worth Over ₹5000 Cr Ignite Investor Hope!

Industrial Goods/Services

|

Updated on 13th November 2025, 5:21 PM

Whalesbook Logo

Reviewed By

Abhay Singh | Whalesbook News Team

Short Description:

Dilip Buildcon reported a net profit of ₹182 crore for the September 2024 quarter, a 22.8% decrease year-on-year, with revenue falling 21.8% to ₹1,925 crore. However, the company secured significant new infrastructure projects totaling over ₹5,000 crore across multiple states, including irrigation, metro, and urban development projects. Operating margins improved to 24.5%, and the net order book stands strong at ₹18,610 crore.

Dilip Buildcon's Profit Dips 23%! But Mega Project Wins Worth Over ₹5000 Cr Ignite Investor Hope!

▶

Stocks Mentioned:

Dilip Buildcon Ltd

Detailed Coverage:

Dilip Buildcon Ltd announced its financial results for the quarter ended September 30, 2024, reporting a net profit of ₹182 crore, a notable decline of 22.8% compared to ₹235 crore in the same period last year. Revenue for the quarter also saw a dip of 21.8%, coming in at ₹1,925 crore from ₹2,461 crore a year prior, indicating a slowdown in project execution.

Despite the top-line and bottom-line shrinkage, the company's operational efficiency improved, with its operating margin expanding to 24.5% from 20.3% in the corresponding quarter last year. EBITDA stood at ₹470.6 crore, a slight decrease of 5.8% year-on-year.

The company's future outlook is bolstered by a robust net order book of ₹18,610 crore as of September 30, 2024. Dilip Buildcon has also been awarded several key projects during the quarter, including an irrigation project worth ₹2,034 crore in Rajasthan, a ₹1,277 crore metro project in Haryana, and a ₹1,115 crore urban development project in Kerala. Other significant wins include a ₹700 crore road project in Tamil Nadu and a ₹260 crore metro-related project in Odisha, along with a ₹279 crore solar power project in Madhya Pradesh.

**Impact** This news has a considerable impact on Dilip Buildcon's stock and the infrastructure sector. The profit and revenue decline might raise short-term concerns, but the substantial new order wins signal strong future revenue streams and operational capability. The improved operating margin is a positive sign of efficiency. Investors will likely focus on the order book growth and the execution of these new projects. Rating: 7/10

**Definitions** EBITDA: Earnings Before Interest, Taxes, Depreciation, and Amortization. It measures a company's operating performance before accounting for financing and accounting decisions. Operating Margin: Calculated as Operating Income divided by Revenue, it shows how much profit a company makes for each dollar of sales after paying for variable costs of production. Net Order Book: The total value of unexecuted orders a company has secured at a specific point in time, representing future revenue potential. Hybrid Annuity Model (HAM): A public-private partnership model where the government pays a significant portion of the project cost upfront, and the developer receives regular payments (annuities) over a period, sharing risks and rewards. EPC: Engineering, Procurement, and Construction. A contract where a single contractor handles all aspects of a project, including design, sourcing materials, and construction.


Healthcare/Biotech Sector

Rainbow Children's Medicare Q2 Profit Drops! Revenue Climbs Amidst Major Leadership Change – Investors Must See This!

Rainbow Children's Medicare Q2 Profit Drops! Revenue Climbs Amidst Major Leadership Change – Investors Must See This!

Marksans Pharma Q2 Results: Profit Climbs 1.5%, Revenue Soars 12% Amidst Global Expansion!

Marksans Pharma Q2 Results: Profit Climbs 1.5%, Revenue Soars 12% Amidst Global Expansion!

Concord Biotech's Profit PLUMMETS 33%, but HUGE Biotech Acquisition & Green Energy Push Could Spark Comeback!

Concord Biotech's Profit PLUMMETS 33%, but HUGE Biotech Acquisition & Green Energy Push Could Spark Comeback!

Akums Profit PLUMMETS 36%! Pharma Giant's Global Expansion Gamble - What Investors Must Know!

Akums Profit PLUMMETS 36%! Pharma Giant's Global Expansion Gamble - What Investors Must Know!

Zydus Lifesciences Bags FDA Green Light for Major US Multiple Sclerosis Drug Launch!

Zydus Lifesciences Bags FDA Green Light for Major US Multiple Sclerosis Drug Launch!


IPO Sector

Crypto King Grayscale Poised for Wall Street Debut: IPO Filing Stuns Market!

Crypto King Grayscale Poised for Wall Street Debut: IPO Filing Stuns Market!